Array BioPharma Inc. has hired Curtis Oltmans as general counsel, the company announced earlier this week. Oltmans, a pharmaceutical in-house veteran, comes to the company from Novo Nordisk Inc., where he most recently served as corporate vice president and GC for North America.
Based in Boulder, Colorado, Array BioPharma specializes in the discovery, development and commercialization of targeted small-molecule drugs to treat cancer patients.
In May, the company announced it had entered into a collaboration with Bristol-Myers Squibb Co. on a potential treatment for patients with metastatic colorectal cancer.
"Curt brings to Array extensive legal and pharmaceutical experience with a record of achievement in developing and leading legal and business initiatives for pharmaceutical companies," CEO Ron Squarer said in a statement. "As our general counsel, Curt will be responsible for developing and managing our company's legal and compliance strategies and related functional areas. He will also fill an important role as a key member of Array's executive committee."
Before joining Novo Nordisk as vice president and deputy GC in 2005, Oltmans served as associate GC at Eli Lilly and Co. for more than 13 years.
He holds degrees from the University of Nebraska and from the school's College of Law.
Oltmans succeeds a retiring John Moore.